LY4337713
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Neoplasms
Conditions
Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma
Trial Timeline
Oct 22, 2025 → Mar 1, 2033
NCT ID
NCT07213791About LY4337713
LY4337713 is a phase 1 stage product being developed by Eli Lilly for Ovarian Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07213791. Target conditions include Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07213791 | Phase 1 | Recruiting |
Competing Products
20 competing products in Ovarian Neoplasms